Alarmins: Awaiting a clinical response

Journal of Clinical Investigation

Volumn 122, Issue 8, 2012, Pages 2711-2719

  Chan, James K ^a   Roth, Johannes ^b   Oppenheim, Joost J ^c   Tracey, Kevin J ^d   Vogl, Thomas ^b   Feldmann, Marc ^a   Horwood, Nicole ^a   Nanchahal, Jagdeep ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Feinstein Institute of Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; BETA DEFENSIN; BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; HEAT SHOCK PROTEIN 60; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHRONIC DISEASE; CHRONIC INFLAMMATION; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; REGENERATIVE MEDICINE; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84864748513     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62423     Document Type: Review

References (149)

1. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17(4):359-365. (Pubitemid 40848537)
2. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science. 2009;323(5922):1683-1684.
3. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-305. (Pubitemid 34303674)
4. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557-566.
5. Zhu S, Li W, Ward MF, Sama AE, Wang H. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets. 2010;9(1):60-72.
6. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139-162.
7. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007;220:35-46. (Pubitemid 350045574)
8. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):578-582.
9. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9(10):1245-1250. (Pubitemid 37279838)
10. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001;29(7 suppl):S121-S125. (Pubitemid 32681594)
11. Rotstein OD. Modeling the two-hit hypothesis for evaluating strategies to prevent organ injury after shock/resuscitation. J Trauma. 2003; 54(5 suppl):S203-S206. (Pubitemid 36758874)
12. Hensler T, et al. Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase. J Trauma. 2002;52(5):962-970. (Pubitemid 34534485)
13. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348(2):138-150. (Pubitemid 36056721)
14. Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36(6):691-709. (Pubitemid 40732303)
15. Martin TR. Cytokines and the acute respiratory distress syndrome (ARDS): a question of balance. Nat Med. 1997;3(3):272-273. (Pubitemid 27112917)
16. Tracey KJ, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662-664. (Pubitemid 18005583)
17. Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12(6):595-601. (Pubitemid 44673437)
18. Neunaber C, et al. Immunomodulation in polytrauma and polymicrobial sepsis - where do we stand? Recent Pat Inflamm Allergy Drug Discov. 2011; 5(1):17-25.
19. Peltz ED, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock. 2009;32(1):17-22.
20. Kohno T, et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res. 2009; 81(3):565-573.
21. Goldstein RS, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock. 2006;25(6):571-574. (Pubitemid 44297016)
22. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251. (Pubitemid 29329996)
23. Abeyama K, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115(5):1267-1274. (Pubitemid 40629045)
24. Yang R, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med. 2006; 12(4-6):105-114. (Pubitemid 44454098)
25. Kim JY, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L958-L965. (Pubitemid 40547924)
26. Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201(7):1135-1143. (Pubitemid 40524681)
27. Watanabe T, et al. The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res. 2005;124(1):59-66. (Pubitemid 40269802)
28. Ogawa EN, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med. 2006; 174(4):400-407. (Pubitemid 44223120)
29. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165(6):2950-2954.
30. Andrassy M, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117(25):3216-3226.
31. Liu K, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 2007;21(14):3904-3916. (Pubitemid 350232348)
32. Muhammad S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008; 28(46):12023-12031.
33. Yang H, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101(1):296-301. (Pubitemid 38084244)
34. Lutterloh EC, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007; 11(6):R122.
35. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Marechal V. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med. 2011;37(6):957-962.
36. Yang D, et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med. 2012;209(1):157-171.
37. Vogl T, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007; 13(9):1042-1049. (Pubitemid 47517513)
38. van Zoelen MA, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med. 2009;180(11):1098-1106.
39. Vandal K, Rouleau P, Boivin A, Ryckman C, Talbot M, Tessier PA. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J Immunol. 2003;171(5):2602-2609. (Pubitemid 37025572)
40. Payen D, et al. Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med. 2008;34(8):1371-1376.
41. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949-955. (Pubitemid 32946067)
42. Liliensiek B, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113(11):1641-1650. (Pubitemid 39071688)
43. Tamaki Y, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol. 2011;38(5):810-820.
44. Manfredi AA, Capobianco A, Bianchi ME, Rovere-Querini P. Regulation of dendritic- and T-cell fate by injury-associated endogenous signals. Crit Rev Immunol. 2009;29(1):69-86.
45. Yang D, Tewary P, de la Rosa G, Wei F, Oppenheim JJ. The alarmin functions of high-mobility group proteins. Biochim Biophys Acta. 2010;1799(1-2):157-163.
46. Dumitriu IE, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174(12):7506-7515. (Pubitemid 40806253)
47. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol. 2007;81(1):59-66. (Pubitemid 46021253)
48. Frosch M, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(3):628-637. (Pubitemid 30394955)
49. Odink K, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987;330(6143):80-82. (Pubitemid 17152420)
50. Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis - from pathophysiology to treatment. Rheumatology (Oxford). 2008;47(2):121-125. (Pubitemid 351168217)
51. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762-3771. (Pubitemid 39643922)
52. van Lent PL, et al. Myeloid-related proteins S100A8/ S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67(12):1750-1758.
53. van Lent PL, et al. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum. 2008;58(12):3776-3787.
54. Loser K, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16(6):713-717.
55. Pullerits R, Jonsson IM, Kollias G, Tarkowski A. Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. Arthritis Res Ther. 2008; 10(3):R72.
56. Sundberg E, et al. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients - a prospective clinical study. Arthritis Res Ther. 2008;10(2):R33.
57. Kokkola R, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48(7):2052-2058. (Pubitemid 36828701)
58. Ostberg T, et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum. 2010; 62(10):2963-2972.
59. Urbonaviciute V, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205(13):3007-3018.
60. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005;5(4):318-330. (Pubitemid 40516157)
61. Kamphuis S, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet. 2005; 366(9479):50-56. (Pubitemid 40956530)
62. Prakken BJ, et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum. 2002;46(7):1937-1946. (Pubitemid 34774527)
63. de Kleer IM, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol. 2004;172(10):6435-6443.
64. Prakken BJ, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004;101(12):4228-4233. (Pubitemid 38405911)
65. Broere F, van der Zee R, van Eden W. Heat shock proteins are no DAMPs, rather 'DAMPERs'. Nat Rev Immunol. 2011;11(8):565.
66. Koffeman EC, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009; 60(11):3207-3216.
67. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11(7):615-628.
68. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-388.
69. Coffelt SB, Scandurro AB. Tumors sound the alarmin(s). Cancer Res. 2008;68(16):6482-6485.
70. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799(1-2):131-140.
71. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34(4):357-364. (Pubitemid 351381290)
72. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622-1631. (Pubitemid 44666730)
73. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci. 2000;113(pt 4):611-620. (Pubitemid 30133039)
74. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004;279(7):5059-5065. (Pubitemid 38220521)
75. Turovskaya O, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29(10):2035-2043.
76. Cheng P, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235-2249.
77. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand- Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008; 181(7):4666-4675.
78. Hiratsuka S, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10(11):1349-1355.
79. Maeda S, et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun. 2007;360(2):394-400. (Pubitemid 47030357)
80. Ellerman JE, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007; 13(10):2836-2848. (Pubitemid 46850704)
81. Chung HW, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.
82. Nestl A, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 2001;61(4):1569-1577. (Pubitemid 34292589)
83. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol. 2003;23(8):2991-2998. (Pubitemid 36403094)
84. Schlueter C, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005;166(4):1259-1263. (Pubitemid 40524448)
85. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637-668. (Pubitemid 32520962)
86. Vogl T, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104(13):4260-4268. (Pubitemid 39620181)
87. Sparvero LJ, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17.
88. Brezniceanu ML, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17(10):1295-1297.
89. Taguchi A, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354-360. (Pubitemid 30337069)
90. Conejo-Garcia JR, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004;10(9):950-958. (Pubitemid 39273736)
91. Coffelt SB, et al. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer. 2008;122(5):1030-1039. (Pubitemid 351214000)
92. Heilborn JD, et al. Antimicrobial protein hCAP18/ LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 2005;114(5):713-719. (Pubitemid 40344432)
93. von Haussen J, et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2008;59(1):12-23.
94. Curtin JF, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1):e10.
95. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9):1050-1059. (Pubitemid 47517504)
96. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008;20(5):518-523.
97. Sun CQ, et al. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 2006;66(17):8542-8549. (Pubitemid 44449167)
98. Bullard RS, et al. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008;45(3):839-848. (Pubitemid 47505263)
99. Hubert P, et al. Defensins induce the recruitment of dendritic cells in cervical human papilloma-virus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J. 2007; 21(11):2765-2775. (Pubitemid 47372744)
100. Economopoulou M, et al. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood. 2005;106(12):3831-3838. (Pubitemid 41739020)
101. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
102. Claus RA, Otto GP, Deigner HP, Bauer M. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med. 2010;10(2):227-235.
103. Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol. 2011;29(3):567-574.
104. Hammer HB, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093-1097. (Pubitemid 47122325)
105. Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol. 1994;21(4):733-738. (Pubitemid 24126774)
106. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 2003; 48(6):1676-1685. (Pubitemid 36682376)
107. Foell D, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet. 2003;361(9365):1270-1272. (Pubitemid 36428584)
108. Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63(2):206-208. (Pubitemid 38122142)
109. Foell D, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010; 303(13):1266-1273.
110. Liao H, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004;50(12):3792-3803. (Pubitemid 39643926)
111. Hammer HB, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150-154.
112. University Hospital, Clermont-Ferrand. Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLi-RAGE). ClinicalTrials.gov. NIH Web site. http:// www.clinicaltrials.gov/ct2/show/NCT01270295? term=NCT01270295&rank=1. Updated January 4, 2011. Accessed March 26, 2012.
113. Glaros T, Larsen M, Li L. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci. 2009;14:3988-3993.
114. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001;4(11):1116-1122. (Pubitemid 34116557)
115. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone. 2009;45(2):367-376.
116. Kim YS, et al. TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci. 2009;14:2845-2856.
117. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci U S A. 2011;108(4):1585-1590.
118. Rouhiainen A, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood. 2004; 104(4):1174-1182. (Pubitemid 39038040)
119. Degryse B, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol. 2001;152(6):1197-1206. (Pubitemid 34280177)
120. Palumbo R, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164(3):441-449. (Pubitemid 38174771)
121. Mitola S, et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol. 2006;176(1):12-15. (Pubitemid 43023243)
122. Limana F, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res. 2005; 97(8):e73-e83.
123. Koczulla R, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-1672. (Pubitemid 38057748)
124. Yang D, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000; 192(7):1069-1074.
125. Straino S, et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol. 2008;128(6):1545-1553. (Pubitemid 351693201)
126. Heilborn JD, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389. (Pubitemid 36298423)
127. Hirsch T, et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med. 2009;11(3):220-228.
128. Wu N, Davidson JM. Migration inhibitory factor-related protein (MRP)8 and MRP14 are differentially expressed in free-electron laser and scalpel incisions. Wound Repair Regen. 2004;12(3):327-336. (Pubitemid 38880441)
129. Trostrup H, et al. S100A8/A9 deficiency in non-healing venous leg ulcers uncovered by multiplexed antibody microarray profiling. Br J Dermatol. 2011; 165(2):292-301.
130. Germani A, Limana F, Capogrossi MC. Pivotal advances: high-mobility group box 1 protein - a cytokine with a role in cardiac repair. J Leukoc Biol. 2007;81(1):41-45. (Pubitemid 46021250)
131. Limana F, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One. 2011;6(6):e19845.
132. Kitahara T, et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res. 2008;80(1):40-46.
133. Oozawa S, et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J. 2008; 72(7):1178-1184. (Pubitemid 351957089)
134. Maroso M, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010; 16(4):413-419.
135. Seeliger S, et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol. 2003;163(3):947-956. (Pubitemid 37040130)
136. Goova MT, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001; 159(2):513-525. (Pubitemid 32751082)
137. Eming SA, et al. Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. J Proteome Res. 2010; 9(9):4758-4766.
138. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275(51):40096-40105. (Pubitemid 32064635)
139. Donato R, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008-1022.
140. Srikrishna G, Panneerselvam K, Westphal V, Abraham V, Varki A, Freeze HH. Two proteins modulating transendothelial migration of leukocytes rec ognize novel carboxylated glycans on endothelial cells. J Immunol. 2001;166(7):4678- 4688. (Pubitemid 32233755)
141. Srikrishna G, et al. Carboxylated glycans mediate colitis through activation of NF-kappa B. J Immunol. 2005;175(8):5412-5422. (Pubitemid 41456427)
142. Travis S, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11(8):713-719. (Pubitemid 41271174)
143. Liu W, Deyoung BR, Chen X, Evanoff DP, Luo Y. RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. J Autoimmun. 2008;30(4):257-265.
144. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors downregulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21(3):251-262. (Pubitemid 34497016)
145. Yang D, Oppenheim JJ. Alarmins and antimicrobial immunity. Med Mycol. 2009;47(suppl 1):S146-S153.
146. Biragyn A, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001;167(11):6644-6653. (Pubitemid 33081603)
147. Biragyn A, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298(5595):1025-1029. (Pubitemid 35247310)
148. Ramanathan V, Goral S, Helderman JH. Renal transplantation. Semin Nephrol. 2001;21(2):213-219. (Pubitemid 32230551)
149. Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol. 2010;185(2):791-794.